Radiopharm Theranostics (RADX) details Starpharma research partnership 6-K

Rhea-AI Filing Summary

Radiopharm Theranostics Limited submitted a Form 6-K as a foreign private issuer, mainly to furnish an announcement it released to the Australian Securities Exchange. The exhibit, titled “Radiopharm Theranostics Partners with Starpharma on Research,” indicates the company has entered into a research-focused partnership with Starpharma, though specific terms are contained in the attached announcement rather than this summary document. The company also clarifies that this Form 6-K, including its exhibit, is being furnished rather than filed under U.S. securities laws and will only be incorporated into other securities filings if specifically referenced.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of September 2025

Commission File Number: 001-41621

RADIOPHARM THERANOSTICS LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐       No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

RADIOPHARM THERANOSTICS LIMITED

EXPLANATORY NOTE

Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on September 30, 2025 titled:

-   “Radiopharm Theranostics Partners with Starpharma on Research”  

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

1

EXHIBITS

Exhibit Number		Description
99.1		Radiopharm Theranostics Partners with Starpharma on Research

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	RADIOPHARM THERANOSTICS LIMITED
Date: September 30, 2025	By:	/s/ Phillip Hains
		Phillip Hains
		Company Secretary

3

FAQ

What does Radiopharm Theranostics (RADX) report in this Form 6-K?

The Form 6-K furnishes an Australian Securities Exchange announcement titled “Radiopharm Theranostics Partners with Starpharma on Research.”

What is the main subject of Radiopharm Theranostics’ ASX announcement?

The attached ASX announcement describes a research partnership between Radiopharm Theranostics and Starpharma.

Is the Radiopharm Theranostics Form 6-K considered filed under the Exchange Act?

No. The company states this Form 6-K, including its exhibit, shall not be deemed to be “filed” for purposes of the Exchange Act.

Will the information in this 6-K be automatically incorporated into other U.S. securities filings?

No. It will only be incorporated by reference into another filing if that filing expressly refers to this Form 6-K.

Who signed the Radiopharm Theranostics Form 6-K?

The Form 6-K was signed on behalf of the company by Phillip Hains, Company Secretary.

Which exhibit is attached to the Radiopharm Theranostics Form 6-K?

Exhibit 99.1 is attached, titled “Radiopharm Theranostics Partners with Starpharma on Research.”